Treatment of Monomorphic Ventricular Tachycardia

Immediate Assessment and Treatment

• The European Society of Cardiology recommends determining hemodynamic stability first, looking for hypotension, altered mental status, chest pain, acute heart failure, or signs of shock 1, 2
• Obtain a 12-lead ECG in all hemodynamically stable patients to confirm monomorphic VT and guide treatment decisions 1, 2, 4

Hemodynamically Unstable Monomorphic VT

• The European Heart Society mandates direct-current cardioversion as a Class I recommendation for hemodynamically unstable monomorphic VT 1, 2, 4, 3
• Provide immediate sedation if the patient is conscious but hypotensive before cardioversion 1, 2, 4

Hemodynamically Stable Monomorphic VT

• The American Heart Association recommends intravenous procainamide as the preferred initial agent for hemodynamically stable monomorphic VT, with a Class IIa recommendation and Level B evidence 1, 2, 5, 3
• The European Society of Cardiology suggests dosing of 10 mg/kg at 50-100 mg/min intravenously over 10-20 minutes 5, 3
• Contraindications for procainamide include severe heart failure or acute myocardial infarction 1, 2, 5, 4

Special Circumstances

• The European Society of Cardiology recommends intravenous verapamil or beta-blockers for patients presenting with LV fascicular VT characterized by RBBB morphology and left axis deviation 1, 2, 4
• For VT associated with acute myocardial ischemia/infarction, the American College of Cardiology recommends intravenous lidocaine, with a dosing of 1 mg/kg initial bolus, followed by 0.5 mg/kg every 8-10 minutes if needed 3

Long-Term Management Considerations

• The European Heart Society recommends catheter ablation as a Class I recommendation for patients with ischemic heart disease and recurrent ICD shocks due to sustained VT 1, 2, 4
• Catheter ablation should be considered after a first episode of sustained VT in patients with ischemic heart disease and an ICD, with a Class IIa recommendation 1, 2, 4